Radiological Aspects of the New “International Multidisciplinary Classification of Lung Adenocarcinoma”: Methodological Bases and Own Experience (original) (raw)
Related papers
Journal of Modern Oncology
Background. The combination of several diagnostic methods is used to predict treatment outcomes, assess overall survival, and increase the positive predictive value of detecting malignant lung and bronchial tumors. Aim. To evaluate the diagnostic value of the CLIA-СА-62 chemiluminescence immunoassay reagent kit for the detection of early (IaIIb) and advanced (IIIac) stages of lung cancer (LC) in a double-blind clinical study and to assess the use of the CA-62 cancer antigen as a supportive decision-making tool in LC diagnosis in patients with suspicious changes on the tomogram or as a tool for pre-screening of LC prior to computed tomography (CT) to increase diagnostic sensitivity in the detection of early (I and II) stages of LC. Materials and methods. A blinded clinical study was conducted on 304 clinically verified serum samples, including 141 samples from patients with non-small cell LC (NSCLC), 133 healthy volunteers, and 30 chronic obstructive pulmonary disease patients. Quant...
[Radiology report: past, present and future]
Vestnik rentgenologii i radiologii
The analysis of literature data showed that the creation and implementation of a new form of radiology reports into clinical practice is an actual problem of modern medicine. Although imaging modalities have undergone dramatic evolution over the past century, radiology reporting has remained largely static, in both content and structure. In recent years the necessity to create a structured reporting is widely discussed in the literature. A universal format of radiology report hasn't been found yet. The standard of reporting system is absent, a wide variety of styles in radiology reporting currently exists. The challenging goal is improvement of existing protocols and creation of a new form of radiology reports--the protocols of the future.
Journal of Modern Oncology
Background. Morphological verification of central and peripheral focal lung neoplasms is a difficult task for modern minimally invasive methods of differential diagnosis. The use of transthoracic trepanobiopsy of lung neoplasms under the control of computed tomography (CT) allows you to obtain informative, histological material and make a correct diagnosis. Aim. The aim of the study was to determine the possibility and safety of performing transthoracic trepanobiopsy of lung tumors under the control of CT in patients who are on an outpatient appointment in a third-level institution in order to obtain informative histological material. Materials and methods. From January 2020 to April 2021, 65 patients underwent transthoracic trepanobiopsy of focal lung neoplasms under the control of CT on an outpatient basis in the polyclinic department of the Ostroverkhov Kursk Cancer Research and Clinical Center. Results. The average time spent on performing a biopsy, with preliminary marking unde...
Lung Ultrasound: new Opportunities for a Cardiologist
Kardiologiia, 2020
This review focused on ultrasound examination of lungs, a useful complement to transthoracic echocardiography (EchoCG), which is superior to chest X-ray in the diagnostic value. The lung acoustic window always remains open and allows obtaining high-quality images in most cases. For a cardiologist, the major points of the method application are determination of pleural effusion and lung congestion. This method has a number of advantages: it is time-saving; cost-effective; portable and accessible; can be used in a real-time mode; not associated with radiation; reproducible; and highly informative. The ultrasound finding of wet lungs would indicate threatening, acute cardiac decompensation long before appearance of clinical, auscultative, and radiological signs of lung congestion. Modern EchoCG should include examination of the heart and lungs as a part of a single, integrative ultrasound examination.
Main achievements of low-dose computed tomography in lung cancer screening
Tuberculosis and Lung Diseases, 2021
The objective of the study : to summarize current data on the use of low-dose computed tomography (LDCT) for lung cancer screening (LCS). Subjects and methods : Relevant articles published from 2016 to 2019 were searched for the following key words: lung cancer screening, low-dose computed tomography, ultra-low-dose computed tomography. The search was performed in the open databases of PubMed, Google Scholar, Elibrary. 23 Russian and 778 English publications were found. Among them, relevant publications with high citation indices were selected. Results . By 2019, there have been significant changes in the methodology of LDCT in LCS, and these changes can be considered as one of the priority state areas of modern health care. The article considers the main and potential additional goals of screening for lung cancer, the parameters of inclusion into lung cancer risk groups according to the data of various global studies. It describes data on the recommended maximum permissible doses o...
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
Journal of Modern Oncology, 2021
Lung cancer has the highest morbidity rate among all malignant tumors in men and the highest mortality rate in men and women in Russia. In total, 49 145 new cases of lung cancer were registered (diagnosed) in Russia in 2019. The majority of cases are related to exogenic carcinogens and mainly tobacco smoke. For several decades surgical resection with preoperative cytotoxic therapy was an optimal approach for maximal cure rate. This year recommendations were updated with new strategies including adjuvant anti-PD-L1 atezolizumab following completion of chemotherapy in PD-L1 positive patients and osimertinib for EGFR mutated cases. For this moment available data suggest the increase in disease free survival. Strategic approach to treatment for inoperable patients varies according to the status of driver mutations. New approach includes pretreatment option of testing for a wide spectrum of alterations with NGS based panels. Significant changes were incorporated into treatment of ALK mut...
Issledovaniâ i praktika v medicine, 2022
More than 1.8 million of new cases of lung cancer (LC) are registered each year worldwide. LC is the leading cause of cancer death in both developing and developed countries, and the 5-years survival rate is as low as 19 %. Many factors explain such unsatisfactory outcomes, including the LC diagnosis at an advanced stage, when the currently available treatments can rarely provide cure. Biomarkers are used to assess the development risks, screening, diagnosis, monitoring, and prognosis, and to personalize the LC treatment. Clinical use of biomarkers is essential for the identification of a high-risk group for screening for LC and differentiating early LC from benign pulmonary lesions. Current trends in the development of LC biomarkers involve the integration of molecular biomarkers with clinical and radiological characteristics using artificial intelligence for the development of imaging biomarkers, and using highly sensitive technologies such as next-generation sequencing for molecular research. LC biomarkers are now at all stages of development, from discovery to clinical trials requiring high-quality clinical validation. Reliable biomarkers are especially needed to differentiate malignant and benign lesions in the lung tissue and to identify those at greatest risk of developing lung cancer. Scientific advances in understanding LC have led to the development of biomarkers that demonstrate sufficient accuracy in clinical validation studies. Promising trends in the development of LC biomarkers include highly sensitive and increasingly accessible NGS and radiomics technologies, along with the use of easily collected biomaterials, which in combination with other tumor characteristics contribute to the development of biomarkers for assessing the LC development risks, diagnosis, monitoring, prognosis and personalized therapy. This review focuses on the development, current application, and future trends in the use of LC biomarkers.
VESTNIK KHIRURGII IMENI I.I.GREKOVA
В в е д е н и е. Заболеваемость раком лёгкого (РЛ) в мире достигает 1 300 000 случаев [3, 6, 8, 12, 16]. В Российской Федерации РЛ находится на 2-м месте в общей структуре онкологических заболеваний (11,6 %) и на 1-м (20,4 %) среди злокачественных опухолей у мужчин. Число заболевших им ежегодно превышает 50 000 человек, причём умирают от него 90-96 % заболевших, а свыше 50 % из нихуже в год постановки диагноза. Несмотря на бурное развитие диагностических и лечебных технологий, 5-летняя выживаемость при РЛ во всех странах за последние полвека не меняется, не превышая 15-20 %. При этом известно, что эффективность лечения находится в прямой зависимости от распространённости опухоли на момент начала реализации клинических мероприятий. Так, если для I стадии 5-летняя выживаемость может достигать 70-80 %, то для IV-не превышает 5 %. Ранняя диагностика РЛ до настоящего времени остаётся нерешённой проблемой, и более 2 / 3 заболевших начинают специализированное лечение, имея местно-распространённые либо генерализованные формы опухоли [1, 6, 7, 13].
Endoscopic ultrasound examination in the detection of metastatic lung lesion
Onkologiya. Zhurnal imeni P.A.Gertsena, 2018
Objective-to show the efficiency of endobronchial ultrasound (EBUS) examination in patients with suspected pulmonary metastasis. Subject and methods. In 2010 to 2016, a total of 65 patients with suspected pulmonary metastasis underwent bronchoscopy using ultrasound miniprobes at a scanning frequency of 20 MHz to search and verify peripheral lung neoplasms. Results. The sensitivity of the technique in the group was 63.1%. At the same time, the specificity for 5 patients who underwent surgical treatment after endoscopic verification of lung metastases was 100%. Conclusion. Ultrasonic bronchoscopy is an effective, relatively simple and easy-to-use tool for diagnosing metastatic lung lesion.